Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Prestige Consumer Healthcare Inc.    PBH

PRESTIGE CONSUMER HEALTHCARE INC.

(PBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Prestige Consumer Healthcare : to Release Fiscal 2021 Second Quarter Earnings Results

10/07/2020 | 05:01pm EST

TARRYTOWN, N.Y., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2021 second quarter earnings release on Thursday, November 5, 2020 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

To participate via phone listeners calling from the U.S. and Canada may dial 844-233-9440, or 574-990-1016 internationally, using the conference ID 4199894. The Company will provide a live Internet webcast as well as an archived replay, which can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com.

Telephonic replays will be available for approximately one week following completion of the live call and can be accessed at 855-859-2056 within North America, and at 404-537-3406 from outside North America. The conference ID is 4199894.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.

Investor Relations Contact

Phil Terpolilli, CFA, 914-524-6819

irinquiries@prestigebrands.com


New Prestige Consumer Healthcare Logo.jpg

Source: Prestige Consumer Healthcare Inc.

2020 GlobeNewswire, Inc., source Press Releases

All news about PRESTIGE CONSUMER HEALTHCARE INC.
01/12PRESTIGE CONSUMER HEALTHCARE : ICR Conference 2021 Presentation
PU
01/08Prestige Consumer Healthcare Inc. to Release Fiscal 2021 Third Quarter Earnin..
GL
2020DA Davidson Adjusts Prestige Consumer Healthcare's Price Target to $39 from $..
MT
2020Prestige Consumer Healthcare Fiscal Q2 Adjusted Profit, Revenue Top Expectati..
MT
2020PRESTIGE BRANDS : Fiscal 2Q Earnings Snapshot
AQ
2020PRESTIGE CONSUMER HEALTHCARE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL..
AQ
2020PRESTIGE CONSUMER HEALTHCARE INC. : Results of Operations and Financial Conditio..
AQ
2020PRESTIGE CONSUMER HEALTHCARE : Reports Fiscal 2021 Second Quarter Results
AQ
2020Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Second Quarter Results
GL
2020PRESTIGE CONSUMER HEALTHCARE : to Release Fiscal 2021 Second Quarter Earnings Re..
AQ
More news
Financials (USD)
Sales 2021 927 M - -
Net income 2021 164 M - -
Net Debt 2021 - - -
P/E ratio 2021 11,8x
Yield 2021 -
Capitalization 1 908 M 1 908 M -
Capi. / Sales 2021 2,06x
Capi. / Sales 2022 2,03x
Nbr of Employees 520
Free-Float 92,2%
Chart PRESTIGE CONSUMER HEALTHCARE INC.
Duration : Period :
Prestige Consumer Healthcare Inc. Technical Analysis Chart | PBH | US74112D1019 | MarketScreener
Technical analysis trends PRESTIGE CONSUMER HEALTHCARE INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 42,75 $
Last Close Price 38,08 $
Spread / Highest target 26,1%
Spread / Average Target 12,3%
Spread / Lowest Target -2,84%
EPS Revisions
Managers and Directors
NameTitle
Ronald M. Lombardi Chairman, President & Chief Executive Officer
Jeff Zerillo Senior Vice President-Operations
Christine Sacco Chief Financial Officer
John E. Byom Independent Director
Gary E. Costley Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PRESTIGE CONSUMER HEALTHCARE INC.9.21%1 908
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159